iBio (IBIO) Q3 2026 earnings summary

Executive summary

• Focused on AI-driven discovery and development of precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases, with all therapeutics in preclinical stages and no clinical trials completed as of March 31, 2026.

• Received regulatory clearance to initiate Phase 1 clinical trial of IBIO-600 in Australia for obesity treatment, with first participant dosing expected in Q2 2026.

• Pipeline expanded to include a bispecific antibody targeting PH-HFpEF and additional programs in obesity and related indications.

• Strategic collaborations, notably with AstralBio, have expanded the pipeline and provided exclusive licenses for key antibody candidates.

• Presented new preclinical data showing IBIO-610 reduced visceral fat by 6.7% and total fat mass by 5.2% in obese non-human primates.

Financial highlights

• Net loss for the three months ended March 31, 2026 was $7.7 million ($0.06 per share), compared to $4.9 million ($0.49 per share) in the prior year quarter.

• Net loss for the nine months ended March 31, 2026 was $22.4 million ($0.25 per share), up from $13.2 million ($1.44 per share) year-over-year.

• Total operating expenses for the nine months ended March 31, 2026 were $23.9 million, up from $13.6 million in the prior year period, driven by increased R&D and a $5 million impairment charge.

• Cash, cash equivalents, and investments in debt securities totaled $74.8 million as of March 31, 2026.

• R&D expenses increased to $3.3 million for the quarter, up from $1.9 million year-over-year, with G&A expenses rising to $5.1 million from $3 million, mainly due to a $2.5 million impairment.

Outlook and guidance

• Current cash position is expected to fund operations for at least 12 months from the filing date, with sufficient liquidity to support advancement of the pipeline into clinical stages.

• Cash runway extended into Q4 of fiscal year 2028 following $17 million in gross proceeds from warrant exercises.

• Management anticipates continued operating losses and negative cash flows as clinical trials commence and R&D spending increases.

• Future funding needs may be met through additional equity offerings, collaborations, or asset out-licensing.